Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy and safety of Ba253BINEB during
the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan®
aerosol) as the comparator drug.